MK0966; rofecoxib / Duration of Treatment: 24 weeks + Comparator: placebo / Duration of Treatment: 24 weeks
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Adenomatous Polyposis Coli
Conditions
Adenomatous Polyposis Coli
Trial Timeline
Aug 6, 2002 → Oct 11, 2004
NCT ID
NCT00140894About MK0966; rofecoxib / Duration of Treatment: 24 weeks + Comparator: placebo / Duration of Treatment: 24 weeks
MK0966; rofecoxib / Duration of Treatment: 24 weeks + Comparator: placebo / Duration of Treatment: 24 weeks is a approved stage product being developed by Merck for Adenomatous Polyposis Coli. The current trial status is terminated. This product is registered under clinical trial identifier NCT00140894. Target conditions include Adenomatous Polyposis Coli.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00140894 | Approved | Terminated |
Competing Products
3 competing products in Adenomatous Polyposis Coli
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Celecoxib + Placebo | Pfizer | Phase 3 | 76 |
| Celecoxib | Pfizer | Pre-clinical | 22 |
| REC-4881 + Placebo | Recursion Pharmaceuticals | Phase 1/2 | 36 |